The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 07, 2017

Filed:

Feb. 01, 2013
Applicant:

Haemostatix Limited, Nottingham, Nottinghamshire, GB;

Inventors:

Greg Walker, Dunedin, NZ;

Sarah Margaret Middleton, Nottingham, GB;

Assignee:

HAEMOSTATIX LIMITED, Nottingham, Nottinghamshire, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 9/00 (2006.01); A61L 24/00 (2006.01); A61L 15/32 (2006.01); A61L 15/42 (2006.01); A61L 15/44 (2006.01); A61L 24/10 (2006.01);
U.S. Cl.
CPC ...
A61L 24/0015 (2013.01); A61L 15/325 (2013.01); A61L 15/425 (2013.01); A61L 15/44 (2013.01); A61L 24/0036 (2013.01); A61L 24/0073 (2013.01); A61L 24/108 (2013.01); A61L 2300/25 (2013.01); A61L 2300/252 (2013.01); A61L 2300/418 (2013.01); A61L 2300/606 (2013.01); A61L 2400/04 (2013.01); A61L 2400/18 (2013.01);
Abstract

Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.


Find Patent Forward Citations

Loading…